As of Oct 02
| -0.39 / -4.39%|
The 5 analysts offering 12-month price forecasts for ADMA Biologics Inc have a median target of 20.00, with a high estimate of 24.00 and a low estimate of 15.00. The median estimate represents a +135.29% increase from the last price of 8.50.
The current consensus among 5 polled investment analysts is to Buy stock in ADMA Biologics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.